Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe C. Ferber

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
ALTEX|January 1, 1992
[Monoclonal antibodies: Comparative methods for in vitro production]René W. Fischer, Philippe C. Ferber
Open Heart|October 21, 2021
PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER): a real-world studyFd Richard Hobbs, Rizwan I Hussain, Cristina Vitale, et al.
International Journal of Cardiology|October 10, 2022
Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registryLars H Lund, Uwe Zeymer, Andrew L Clark, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|March 16, 2021
Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registryUwe Zeymer, Andrew L Clark, Vivencio Barrios, et al.
ESC Heart Failure|September 15, 2022
Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registryAldo P Maggioni, Andrew L Clark, Vivencio Barrios, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
ALTEX|January 1, 1992
[Monoclonal antibodies: Comparative methods for in vitro production]René W. Fischer, Philippe C. Ferber
Open Heart|October 21, 2021
PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER): a real-world studyFd Richard Hobbs, Rizwan I Hussain, Cristina Vitale, et al.
International Journal of Cardiology|October 10, 2022
Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registryLars H Lund, Uwe Zeymer, Andrew L Clark, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|March 16, 2021
Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registryUwe Zeymer, Andrew L Clark, Vivencio Barrios, et al.
ESC Heart Failure|September 15, 2022
Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registryAldo P Maggioni, Andrew L Clark, Vivencio Barrios, et al.
Pageof 1